Core Viewpoint - The financial performance and stock activity of Xiaofang Pharmaceutical indicate a stable growth trajectory, with a slight increase in revenue and net profit, while the financing situation remains relatively low compared to historical levels [1][2]. Group 1: Financial Performance - For the period from January to September 2025, Xiaofang Pharmaceutical achieved a revenue of 397 million yuan, representing a year-on-year growth of 8.17% [2]. - The net profit attributable to the parent company for the same period was 170 million yuan, reflecting a year-on-year increase of 5.09% [2]. Group 2: Stock and Financing Activity - On November 11, Xiaofang Pharmaceutical's stock price increased by 0.09%, with a trading volume of 23.27 million yuan [1]. - The financing buy-in amount on the same day was 2.76 million yuan, while the financing repayment was 1.95 million yuan, resulting in a net financing buy-in of 816,500 yuan [1]. - The total financing and securities lending balance as of November 11 was 89.99 million yuan, which accounts for 5.16% of the circulating market value, indicating a low financing balance compared to the past year [1]. - There were no securities lent or sold on November 11, with the securities lending balance remaining at zero, which is at a high level compared to the past year [1]. Group 3: Shareholder Information - As of October 31, the number of shareholders for Xiaofang Pharmaceutical was 13,400, an increase of 0.31% from the previous period [2]. - The average number of circulating shares per shareholder was 4,070, which decreased by 0.31% compared to the previous period [2]. - Since its A-share listing, Xiaofang Pharmaceutical has distributed a total of 353 million yuan in dividends [3].
小方制药11月11日获融资买入276.24万元，融资余额8998.52万元